A Phase 1 interventional study of Diazoxide Choline Controlled-Release Tablet in Hypertriglyceridmia, sponsored by Essentialis, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-10.
Sponsored by Essentialis, Inc. · Phase 1 and Interventional
Once a day oral administration with DCCR is the optimal dosing regimen
POPULATION The population will consist of generally healthy subjects with elevated fasting triglyceride levels in the range of ≥ 150 mg/dL and ≤ 1500 mg/dL at the Screening Visit.
Number of Subjects A total of 10 subjects will be enrolled in the study at 1 site in the USA.
Essentialis, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Basic requirements
Body mass index (BMI) between 22 and 35 kg/m2
Specific laboratory test results
Exclusion Criteria:
Medications: recent, current, anticipated
Thiazide diuretics within 2 weeks prior to Screening Visit
History of allergic reaction or significant intolerance to:
Sulfonamides
Lifestyle changes
Subjects intending to change exercise habits, and/or quit smoking
Specific diagnoses, medical conditions and history
Any other clinically significant endocrine, cardiovascular, pulmonary, neurological, psychiatric, hepatic, gastrointestinal, hematological, renal, or dermatological disease interfering with the assessments of the investigational drug, according to the Investigator
Specific laboratory test results
DCCR Treatment 290 mg diazoxide choline
Drug: Diazoxide Choline Controlled-Release Tablet
DCCR 290 mg once a day for 10 days
Steady-state Pharmacokinetic profile of DCCR
* Mean concentration-time profile for diazoxide * Steady-state pharmacokinetic parameters of diazoxide (Cmax(ss), AUC0-inf(ss), and CL/F) * Terminal elimination half-life (t½) of diazoxide
Time frame: 10 days
Concentration-Time profile of major metabolite
* Steady-state pharmacokinetic parameters (Cmax(ss) and AUC0-inf(ss)) of the major metabolite of diazoxide * Terminal elimination half-life (t½) of the major metabolite of diazoxide * Metabolite-to-parent ratios at steady-state in terms of Cmax(ss) and AUC0-inf(ss)
Time frame: 10 days
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Essentialis, Inc.